BioVaxys Technology (TSE:BIOV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioVaxys Technology Corp has secured a 48-kilogram supply of GMP-grade lipids to advance the production of its DPX-based vaccines, anticipating a significant ramp-up in preclinical and clinical programs. This acquisition is expected to save the company over a year in manufacturing lead time. BioVaxys continues to innovate with its patented DPX platform, aiming to deliver robust immune responses for various medical applications.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.